Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00104026
Other study ID # 050103
Secondary ID 05-D-0103
Status Completed
Phase N/A
First received February 18, 2005
Last updated June 30, 2017
Start date February 15, 2005
Est. completion date April 19, 2011

Study information

Verified date April 19, 2011
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will examine common features of gingival overgrowth (excessive growth of the gums around the teeth) that develops in patients with the hereditary form of the condition and in those who develop the condition as a side effect of medications. A better understanding of gingival overgrowth may help scientists develop medications with fewer oral side effects.

Patients of any age with hereditary gingival fibromatosis and their blood relatives, and patients of any age with gingival overgrowth who are taking medications associated with development of the disorder, including phenytoin (diphenylhydantoin or Dilantin), cyclosporine, and calcium-channel blockers, may be eligible for this study.

Participants undergo a medical and dental history, including a history of medication use; detailed examination of the teeth, periodontium, head, and neck; photographs of teeth with gingival overgrowth; dental x-rays; and blood tests. DNA is extracted from a blood sample to look for genes related to gingival overgrowth.

Patients with gingival overgrowth are offered two options, as follows:

- Tissue biopsy: A tissue sample is taken from each affected site, with a maximum of three biopsies. For the procedure, lidocaine is first injected into the gum to numb the tissue. Then, a cookie-cutter instrument is pushed into the numbed skin, and a small piece of tissue is removed.

- Gingivectomy: Surgical removal of the overgrown gingival.


Description:

The purpose of this protocol is twofold: 1) to continue identification of genes associated with hereditary gingival fibromatosis (HGF), a type of gingival overgrowth 2) to investigate the genes up-regulated by medications that induce gingival overgrowth. These studies will establish if common mechanisms are involved in the hereditary and drug-induced processes. If a common pathway is identified, it could lead to the development of assays that could be used to screen new medications for their potential deleterious effects on periodontal tissues. In addition, understanding the mechanisms involved in gingival overgrowth could lead to the development of tissue engineering approaches to repair gingival defects. Genes will be identified from DNA samples collected from patients with hereditary gingival fibromatosis. These will be compared with DNA and tissue samples taken from patients taking medications known to induce gingival overgrowth (phenytoin, cyclosporine and calcium channel blockers).


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date April 19, 2011
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 2 Years to 80 Years
Eligibility - INCLUSION CRITERIA:

Patients of any age, gender, and racial/ethnic group with hereditary gingival fibromatosis (HFG) as diagnosed with HGF by clinical appearance that consists of attached gingival covering the lower 1/3 or more of the clinical crowns of teeth in an individual not taking medications associated with gingival changes.

Blood relatives of affected individuals who are at risk of inheriting HGF.

Patients of any age, gender, and racial/ethnic group taking one of the three medications associated with drug-induced gingival overgrowth (phenytoin diphenylhydantoin or Dilantin, cyclosporine, or calcium-channel blockers).

Patients with six or more teeth.

EXCLUSION CRITERIA:

Patients with significant cognitive impairment.

Pregnant patients or lactating patients.

Patients unwilling to give informed consent.

Patients with less than six teeth.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Dental and Craniofacial Research (NIDCR)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Boratynska M, Radwan-Oczko M, Falkiewicz K, Klinger M, Szyber P. Gingival overgrowth in kidney transplant recipients treated with cyclosporine and its relationship with chronic graft nephropathy. Transplant Proc. 2003 Sep;35(6):2238-40. — View Citation

Casetta I, Granieri E, Desiderá M, Monetti VC, Tola MR, Paolino E, Govoni V, Calura G. Phenytoin-induced gingival overgrowth: a community-based cross-sectional study in Ferrara, Italy. Neuroepidemiology. 1997;16(6):296-303. — View Citation

Ellis JS, Seymour RA, Taylor JJ, Thomason JM. Prevalence of gingival overgrowth in transplant patients immunosuppressed with tacrolimus. J Clin Periodontol. 2004 Feb;31(2):126-31. — View Citation

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04030767 - Evaluating Lip Repositioning for the Treatment of Excess Gingival Display With and Without Pretreatment With Botox Phase 1
Recruiting NCT01286298 - Diode Laser in Gingival Enlargement Related to Orthodontics N/A
Completed NCT03569683 - Comparison Between Laser, Synthetic Gel and Herbal Gel as Topical Agents After Gum Surgery N/A
Completed NCT00781196 - Folic Acid Supplementation in Phenytoin Induced Gingival Overgrowth Phase 3
Completed NCT01821157 - Flapless Esthetic Crown Lengthening for the Treatment of Excessive Gingival Display N/A
Completed NCT04805463 - Different Platelet Concentrates After Gingivectomy and Gingivoplasty Evaluation of Its Effect on Early Wound Healing. N/A
Completed NCT03514316 - Scalpel Versus Laser Gingivectomy in Orthodontic Patients in the Management of Periodontal Health N/A
Completed NCT03435068 - Soft Tissue Wound Healing Following Different Gingivectomy Techniques N/A